CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer
Status:
Recruiting
Trial end date:
2023-06-11
Target enrollment:
Participant gender:
Summary
This phase I trial studies how well CBM588 works when given together with nivolumab and
ipilimumab in treating patients with kidney cancer that is stage IV or has spread to other
places in the body (advanced). CBM588 is a probiotic that may help to increase the effect of
immunotherapy. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab,
may help the body's immune system attack the cancer, and may interfere with the ability of
tumor cells to grow and spread. Giving CBM588, nivolumab, and ipilimumab may work better in
treating patients with kidney cancer.